1 active not recruiting, 1 not yet recruiting, 1 recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
Follow lorlatinib: new trials by email Literature Review of lorlatinib trials Research Report on lorlatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma lorlatinib, concurrent/sequential platinum-based chemoradiotherapy - Neoadjuvant Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Guangdong Association of Clinical Trials | 36 | 2025-03-01 | 2025-03-05 |
| Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular | Phase 3 | Recruiting | Children's Oncology Group | 750 | 2018-05-14 | 2026-08-25 |
| A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC Lorlatinib, Crizotinib - Carcinoma, Non-Small-Cell Lung | Phase 3 | Active not recruiting | Pfizer | 296 | 2017-04-27 | 2025-11-25 |
Adenocarcinoma of Lung (1) · Carcinoma, Non-Small-Cell Lung (1) · Ganglioneuroblastoma (1) · Neuroblastoma (1)
Children's Oncology Group (1) · Guangdong Association of Clinical Trials (1) · Pfizer (1)
Canada (2) · United States (2) · Argentina (1) · Australia (1) · Belgium (1) · China (1) · Czechia (1) · France (1) · Germany (1) · Hong Kong (1) · India (1) · Italy (1) · Japan (1) · Mexico (1) · Netherlands (1)
E E Ke, M.D. (1) · Steven G DuBois (1)
PMID 28501139, PMID 29074098, PMID 33207094, PMID 34028986, PMID 34585621, PMID 35605188, PMID 36535300, PMID 37295609, PMID 38819031, PMID 39360949, PMID 40024442, PMID 41124598, PMID 42781551, PMID 42872552
2023 (1), U10CA180886 (1)